参考文献/References:
[1] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789.
[2] Hao G,Wang X,Chen Z,et al. Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey,2012-2015[J]. Eur J Heart Fail,2019,21(11):1329-1337.
[3] Authors/Task Force Members,McDonagh TA,Metra M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). With the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur J Heart Fail,2022,24(1):4-131.
[4] Martens P,Nuyens D,Rivero-Ayerza M,et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol,2019,108(10):1074-1082.
[5] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2022,79(17):e263-e421.
[6] Mohan P,Brutsaert DL,Paulus WJ,et al. Myocardial contractile response to nitric oxide and cGMP[J]. Circulation,1996,93(6):1223-1229.
[7] Gupta D,Georgiopoulou VV,Kalogeropoulos AP,et al. Nitrate therapy for heart failure:benefits and strategies to overcome tolerance[J]. JACC Heart Fail,2013,1(3):183-191.
[8] Breitenstein S,Roessig L,Sandner P,et al. Novel sGC stimulators and sGC activators for the treatment of heart failure[J]. Handb Exp Pharmacol,2017,243:225-247.
[9] Aimo A,Castiglione V,Borrelli C,et al. Oxidative stress and inflammation in the evolution of heart failure:from pathophysiology to therapeutic strategies[J]. Eur J Prev Cardiol,2020,27(5):494-510.
[10] Sandner P. From molecules to patients:exploring the therapeutic role of soluble guanylate cyclase stimulators[J]. Biol Chem,2018,399(7):679-690.
[11] Hulot JS,Trochu JN,Donal E,et al. Vericiguat for the treatment of heart failure:mechanism of action and pharmacological properties compared with other emerging therapeutic options[J]. Expert Opin Pharmacother,2021,22(14):1847-1855.
[12] Tsch?pe C,Pieske B. [New therapy concepts for heart failure with preserved ejection fraction][J]. Herz,2015,40(2):194-205.
[13] Evgenov OV,Pacher P,Schmidt PM,et al. NO-independent stimulators and activators of soluble guanylate cyclase:discovery and therapeutic potential[J]. Nat Rev Drug Discov,2006,5(9):755-768.
[14] 毕淑利,姚朱华. 作用于环磷酸鸟苷的抗心力衰竭药物作用机制及研究进展[J]. 心血管病学进展,2022,43(8):735-738.
[15] Nakai T,Perl NR,Barden TC,et al. Discovery of IWP-051,a novel orally bioavailable sGC stimulator with once-daily dosing potential in humans[J]. ACS Med Chem Lett,2016,7(5):465-469.
[16] Dasgupta A,Bowman L,D’Arsigny CL,et al. Soluble guanylate cyclase:a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J]. Clin Pharmacol Ther,2015,97(1):88-102.
[17] 高源,郑刚,李嫣红,等. 维利西呱治疗心力衰竭新进展[J]. 心血管病学进展,2021,42(8):698-701.
[18] Follmann M,Ackerstaff J,Redlich G,et al. Discovery of the soluble guanylate cyclase stimulator vericiguat(BAY 1021189) for the treatment of chronic heart failure[J]. J Med Chem,2017,60(12):5146-5161.
[19] 皮淑芳,丁冉,赵云,等. 可溶性鸟苷酸环化酶激动剂维利西呱的研究进展[J]. 世界临床药物,2021,42(4):237-240.
[20] Wilck N,Markó L,Balogh A,et al. Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction[J]. JCI Insight,2018,3(4):e96006.
[21] Boettcher M,Loewen S,Gerrits M,et al. Pharmacodynamic and pharmacokinetic interaction profile of vericiguat:results from three randomized phaseⅠstudies in healthy volunteers[J]. Clin Pharmacokinet,2021,60(3):337-351.
[22] Boettcher M,Gerisch M,Lobmeyer M,et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat,a soluble guanylate cyclase stimulator:results from preclinical and phaseⅠ healthy volunteer studies[J]. Clin Pharmacokinet,2020,59(11):1407-1418.
[23] Pieske B,Maggioni AP,Lam CSP,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction:results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF(SOCRATES-PRESERVED) study [J]. Eur Heart J,2017,38(15):1119-1127.
[24] Filippatos G,Maggioni AP,Lam CSP,et al. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction(SOCRATES-PRESERVED) study[J]. Eur J Heart Fail,2017,19(6):782-791.
[25] Armstrong PW,Lam CSP,Anstrom KJ,et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction:the VITALITY-HFpEF Randomized Clinical Trial[J]. JAMA,2020,324(15):1512-1521.
[26] 陈晨,刘怿晗,罗敏,等. 可溶性鸟苷酸环化酶激动剂维利西呱在心力衰竭领域的研究进展[J]. 中国医院药学杂志,2022,42(3):333-337.
[27] Gheorghiade M,Greene SJ,Butler J,et al. Effect of vericiguat,a soluble guanylate cyclase stimulator,on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction:the SOCRATES-REDUCED randomized trial[J]. JAMA,2015,314(21):2251-2262.
[28] Armstrong PW,Roessig L,Patel MJ,et al. A multicenter,randomized,double-blind,placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator:the VICTORIA Trial[J]. JACC Heart Fail,2018,6(2):96-104.
[29] 刘平,邱博,吴惠珍. 维利西呱治疗心力衰竭的药理作用与临床评价[J]. 中国临床药理学与治疗学,2022,27(2):212-218.
[30] Armstrong PW,Pieske B,Anstrom KJ,et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2020,382(20):1883-1893.
[31] Voors AA,Mulder H,Reyes E,et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction:insights from the VICTORIA(Vericiguat Global Study in Subjects with HFrEF) trial[J]. Eur J Heart Fail,2021,23(8):1313-1321.
[32] Ponikowski P,Alemayehu W,Oto A,et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction:insights from the VICTORIA trial[J]. Eur J Heart Fail,2021,23(8):1300-1312.
[33] Ezekowitz JA,Zheng Y,Cohen-Solal A,et al. Hemoglobin and clinical outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction(VICTORIA)[J]. Circulation,2021,144(18):1489-1499.
[34] Saldarriaga C,Atar D,Stebbins A,et al. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction[J]. Eur J Heart Fail,2022,24(5):782-790.
[35] Ezekowitz JA,O’Connor CM,Troughton RW,et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes:Vericiguat Heart Failure With Reduced Ejection Fraction Study[J]. JACC Heart Fail,2020,8(11):931-939.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(7):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(7):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(7):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(7):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(7):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(7):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(7):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(7):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(7):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(7):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]